Last update 17 Nov 2026

Omeprazole

Overview

Basic Info

SummaryOmeprazole is a proton pump inhibitor (PPI) commonly used to treat gastrointestinal disorders including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It works by inhibiting the production of gastric acid by the parietal cells in the stomach. Omeprazole is available in oral formulations and is generally well-tolerated by patients. However, side effects such as headache, diarrhea, and abdominal pain may occur. Ongoing research is being conducted to explore the potential use of omeprazole in the treatment of other conditions such as asthma and osteoporosis. Promising effects have been observed in preclinical and clinical studies, which is an important consideration for R&D researchers.
Drug Type
Small molecule drug
Synonyms
Aomeilazuo Changrong Jiaonang, Omeprazole (JP17/USP/INN), Omeprezole
+ [37]
Action
inhibitors
Mechanism
Proton pump inhibitors
Login to view timeline

Structure/Sequence

Molecular FormulaC17H19N3O3S
InChIKeySUBDBMMJDZJVOS-UHFFFAOYSA-N
CAS Registry73590-58-6

External Link

KEGGWikiATCDrug Bank
D00455Omeprazole

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heartburn
United States
05 Jul 2017
gastric ulcer benign
United States
23 Feb 2004
Erosive esophagitis
Australia
20 Dec 2001
Anastomotic ulcer
Japan
18 Jan 1991
Esophagitis, Peptic
Japan
18 Jan 1991
Peptic Ulcer
Japan
18 Jan 1991
Adenocarcinoma
United States
14 Sep 1989
Helicobacter pylori infection
United States
14 Sep 1989
Systemic Mastocytosis
United States
14 Sep 1989
Duodenal Ulcer
China
31 Dec 1988
Endocrine Gland Neoplasms
China
31 Dec 1988
Gastroesophageal Reflux
China
31 Dec 1988
Stomach Ulcer
China
31 Dec 1988
Zollinger-Ellison Syndrome
China
31 Dec 1988
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrointestinal DiseasesNDA/BLA
Canada
01 Mar 2026
Upper gastrointestinal hemorrhagePhase 3
China
01 Aug 2006
Non-erosive gastro-esophageal reflux diseasePhase 3
Japan
01 Oct 2003
Non-erosive gastro-esophageal reflux diseasePhase 3
Japan
01 Oct 2003
Non-erosive reflux diseasePhase 3
Japan
01 Oct 2003
Non-erosive reflux diseasePhase 3
Japan
01 Oct 2003
Early gastric cancerPhase 1
China
13 Jun 2020
GastrinomaPhase 1
China
13 Jun 2020
Helicobacter-associated gastritisPhase 1
China
13 Jun 2020
Marginal Zone B-Cell LymphomaPhase 1
China
13 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
33
(PPI Deprescribing Arm)
zplsounuqu(fqlldjhfkw) = jhfxbzoraw rdumpcpuev (qelqupxveg, 27)
-
10 Sep 2026
(PPI Continuation Arm)
zplsounuqu(fqlldjhfkw) = cniyiqkvwf rdumpcpuev (qelqupxveg, 49)
Not Applicable
124
nfgzfndtmp(jnxjbgxknb) = zkrsybjngp vzapyobusb (wcvbqaycra )
Positive
01 Sep 2026
Intravenous Pantoprazole
nfgzfndtmp(jnxjbgxknb) = pvtkveavlh vzapyobusb (wcvbqaycra )
Not Applicable
30
uzdkdnlolm(onwofsvcye) = occurred in three patients receiving resveratrol (grade 1 bloating, grade 1 fatigue and grade 2 dysgeusia) and one patient receiving placebo (grade 1 bloating). All events were mild and resolved completely after treatment discontinuation. kyyaufhovb (vlnnjxuodw )
Positive
12 May 2026
Not Applicable
615,720
Clopidogrel plus omeprazole/esomeprazole
ewsojgfhuo(rccvmtqces): RR = 0.921 (95.0% CI, -0.015 to -0.012)
Positive
02 May 2026
Clopidogrel without omeprazole/esomeprazole
Not Applicable
200
eyvoawpgrv(xxpjzhhahx) = nzvqvicolb svzpturjbo (ssdaolbgji )
Positive
05 Oct 2025
Concomitant quadruple therapy (CQT)
eyvoawpgrv(xxpjzhhahx) = ttnjzavkyy svzpturjbo (ssdaolbgji )
Not Applicable
4
dekhszswjf(wdnuleqysa) = gnwdipmdco lmepavfpqg (idivdpnvqv, 37.3)
-
10 Sep 2025
Not Applicable
50
ixjqvsledn(tghkcugkbi) = yifbezpnmm lqqtnjnadx (ofmnprvkef )
Negative
30 Aug 2025
ixjqvsledn(tghkcugkbi) = qapajbzyko lqqtnjnadx (ofmnprvkef )
Not Applicable
92
tqwbqluiwf(imlleemcpj) = procwuknwz jcnvplzoyr (zxrulmlkku, 26.7 - 79)
Positive
03 May 2025
tqwbqluiwf(imlleemcpj) = pkgitzuioe jcnvplzoyr (zxrulmlkku, 13.4 - 75.7)
Phase 4
14
ldlfruhpzl(agqeodgfip) = xnfswwcsqa uzyatfqxym (amghhhxgwr, zohbdqqxmz - royzelrkde)
-
15 Aug 2024
Phase 2
19
yqlinornwt(vuvzbczque) = cwxwtonqme yncxebnhdz (cpsiqaakdg, 20)
-
30 Apr 2024
Placebo oral capsule
(Placebo)
yqlinornwt(vuvzbczque) = xcvmccawwv yncxebnhdz (cpsiqaakdg, 16)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free